Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer | Zendy

Hope S. Rugo | Zendy; Abhijit Barve | Zendy; Cornelius F. Waller | Zendy; M. Hernández-Bronchud | Zendy; Jay Herson | Zendy; Jinyu Yuan | Zendy; Rajiv Sharma | Zendy; Mark Baczkowski | Zendy; Mudgal Kothekar | Zendy; Subramanian Loganathan | Zendy; Alexey Manikhas | Zendy; Igor Bondarenko | Zendy; Guzel Mukhametshina | Zendy; Gia Nemsadze | Zendy; Joseph D. Parra | Zendy; Maria Luisa T. Abesamis-Tiambeng | Zendy; Kakhaber Baramidze | Zendy; Charuwan Akewanlop | Zendy; Ihor Vynnychenko | Zendy; Virote Sriuranpong | Zendy; Gopichand Mamillapalli | Zendy; Sirshendu Ray | Zendy; Eduardo Patricio Yanez Ruiz | Zendy; Eduardo J. Pennella | Zendy; for the Heritage Study Investigators | Zendy

Open Access

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer

Author(s) -

Hope S. Rugo,

Abhijit Barve,

Cornelius F. Waller,

M. Hernández-Bronchud,

Jay Herson,

Jinyu Yuan,

Rajiv Sharma,

Mark Baczkowski,

Mudgal Kothekar,

Subramanian Loganathan,

Alexey Manikhas,

Igor Bondarenko,

Guzel Mukhametshina,

Gia Nemsadze,

Joseph D. Parra,

Maria Luisa T. Abesamis-Tiambeng,

Kakhaber Baramidze,

Charuwan Akewanlop,

Ihor Vynnychenko,

Virote Sriuranpong,

Gopichand Mamillapalli,

Sirshendu Ray,

Eduardo Patricio Yanez Ruiz,

Eduardo J. Pennella,

for the Heritage Study Investigators

Publication year - 2016

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2016.18305

Subject(s) - trastuzumab , medicine , taxane , biosimilar , metastatic breast cancer , oncology , breast cancer , population , cancer , environmental health

Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy significantly improves outcome in patients with ERBB2 (HER2)-positive metastatic breast cancer; a clinically effective biosimilar may help increase access to this therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog